Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury

DANDAN LI¹, WEIYING REN², ZHILONG JIANG¹ and LEI ZHU¹

Departments of ¹Pulmonary Medicine and ²Gerontology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China

Received February 23, 2018; Accepted July 25, 2018

DOI: 10.3892/mmr.2018.9427

Abstract. Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) is characterized by uncontrolled progressive lung inflammation. Macrophages serve a key role in the pathogenesis of ALI/ARDS. Macrophage pyroptosis is a process of cell death releasing the proinflammatory cytokines interleukin (IL)-1β and IL-18. It was hypothesized that macrophage pyroptosis may partially account for the uncontrolled lung inflammation of ALI/ARDS. In the present study, greater macrophage pyroptosis in lipopolysaccharide (LPS)-treated macrophages and the ALI/ARDS mouse model was observed. The expression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing (NLRP)3 and IL-1β and cleavage of caspase-1 were significantly elevated following LPS treatment accompanied by greater activation of p38 mitogen-activated protein kinase (MAPK) signaling in vitro and in vivo. However, blocking p38 MAPK signaling through the inhibitor SB203580 significantly suppressed the acute lung injury and excessive lung inflammation in vivo, consistent with the reduced expression of the NLRP3 inflammasome and IL-1β and cleavage of caspase-1. Pretreatment of the rat NR8383 macrophage cell line with SB203580 significantly decreased the population of caspase-1+PI+ pyroptotic cells and expression of NLRP3/IL-1β. However, a larger population of Annexin V+PI- apoptotic cells was observed following blocking of the p38 MAPK signaling pathway. The results indicated that blockage of p38 MAPK signaling pathway skewed macrophage cell death from proinflammatory pyroptosis towards non-inflammatory apoptosis. These effects may contribute to attenuated acute lung injury and excessive inflammation in the SB203580-treated mice. The results may provide a novel therapeutic strategy for the treatment of uncontrolled lung inflammation in patients with ALI/ARDS.

Introduction

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is an acute progressing hypoxemic respiratory failure characterized by acute diffuse alveolar damage, influx of neutrophils and protein-rich exudates in alveolar spaces (1). Each year in the United States there are 190,600 cases of acute lung injury, which are associated with 74,500 mortalities and 3.6 million hospital days (2). The underlying immunological mechanisms are still not well defined. The uncontrolled excessive lung inflammation may account for the high mortality rate. Patients usually receive supportive treatments with mechanical ventilation and immunosuppressants, but the therapeutics do not prolong the survival rate in patients and animal models (3,4). Altered alveolar macrophage activation and cell death are considered a major player in the progression of the uncontrolled acute lung inflammation among patients with ALI/ARDS (5-7).

Macrophages are heterogeneous cell components and serve distinct roles in the different stages of diseases (8,9). Following exposure to pathogens, macrophages are activated releasing a variety of cytokines and other mediators. At later stages of the disease, the activated macrophages undergo noninflammatory apoptosis and are finally cleared by monocytes, an important pathological process in inflammation resolution and tissue remodeling (5). However, it is clinically reported that a high percentage of patients with severe sepsis and ALI/ARDS fail to recover from the acute lung inflammation, accompanied by persistent existence of the uncontrolled lung edema and excessive host response to pathogens (10,11). According to previous reports it was hypothesized that the uncontrolled lung inflammation may be caused by both insufficient clearance of dead cells and release of proinflammatory cytokines during immune cell death (12,13). A previous study indicated that macrophages can undergo inflammatory programmed cell death, called pyroptosis, under certain pathological circumstances (12). The pyroptotic cells are identified as caspase-1 and propidium iodide (PI)-double positive cells and are characterized by their release of a large amount of hallmark proteins such as active

Correspondence to: Dr Lei Zhu, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, P.R. China
E-mail: tfzhu@126.com

Key words: acute lung injury and acute respiratory distress syndrome, alveolar macrophages, p38 mitogen-activated protein kinase signaling pathway, pyroptosis, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome
interleukin (IL)-1β and IL-18 (14). Prior to pyroptosis, the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) protein is upregulated and forms a protein complex known as the NLRP3 inflammasome, with apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and pro-caspase-1. Active caspase-1 can stimulate IL-1β and IL-18, causing the release of these active cytokines from pyroptotic cells (15). ASC is an important component of the NLRP3 inflammasome and participates in NLRP3 inflammasome activation (16). It was reported that ASC deficiency caused a defect in NLRP3 inflammasome assembly and protected against liver ischemia/reperfusion damage in animal models through suppression of the caspase-1/IL-1β signaling pathway (17). Other studies also demonstrated that the NLRP3 inflammasome can be activated by neutrophil-derived extracellular histones and complement component 5a, ultimately causing excessive tissue inflammation (18,19).

A body of evidence confirmed that p38 mitogen-activated protein kinase (MAPK) signaling pathway participates in the progression of ALI/ARDS (20,21). p38 MAPK regulates cell growth, proliferation, differentiation, migration, apoptosis and inflammation (22,23). In animals with lipopolysaccharide (LPS)-induced acute lung injury, p38 MAPK expression is upregulated (21). However, there is limited information about the role of p38 signaling pathway in macrophage pyroptosis and uncontrolled lung inflammation in the ALI/ARDS mouse model. In the present study, two macrophage cell lines and an ALI/ARDS mouse model were treated with p38 MAPK inhibitor SB203580 to block p38 MAPK signaling pathway prior to LPS treatment. The present results revealed that blockage of p38 MAPK signaling pathway with SB203580 suppressed macrophage pyroptosis and LPS-induced acute lung injury through negative regulation of NLRP3 inflammasome activation.

Materials and methods

Cell culture and treatments. The murine macrophage cell lines, RAW264.7 and NR8383 cells (American Type Culture Collection, Manassas, VA, USA), were cultured in Roswell Park Memorial Institute (RPMI)-1640 and F-12K medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA), respectively, and supplied with 10% fetal bovine serum, 2 µM glutamine (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin. NR8383 cells were treated with 1 µg/ml LPS (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 4 h at 37°C, with or without pretreatment of 10 mM MAPK p38 inhibitor SB203580 (Selleck Chemicals, Houston, TX, USA) for 1 h at 37°C. Conditioned media and cells were collected for measurement of protein expression levels by enzyme-linked immunosorbent assay (ELISA), reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis.

Animal procedure. A total of 48 10-week-old male wild-type C57BL/6 mice were purchased from Shanghai Model Organisms Center, Inc. (Shanghai, China). All mice were housed at 22°C with 12-h light/dark cycle and free access to food and water. The animal protocol was approved by the Laboratory Animal Care and Use Committee at the Medical College of Fudan University, Zhongshan Hospital. Mice were intratracheally treated with 5 mg/kg LPS with or without 1 h intraperitoneal (i.p.) pretreatment with 20 mg/kg p38 MAPK inhibitor SB203580 (LPS group and SB203580/LPS group) at room temperature. Mice received PBS, and the same doses of SB203580 were used as controls (PBS and SB203580 groups). Following 24 h LPS/PBS treatment, collection of bronchoalveolar lavage fluid (BAL) was performed by intratracheal injection of 0.5 ml of PBS followed by gentle aspiration. The lavage was repeated three times and the recovery rate was >90%. The collected BAL fluid was centrifuged at 400 x g for 5 min at 4°C and cell pellets were suspended in 1 ml of PBS and cell count was manually measured with a hemocytometer by light microscopy. The supernatant of BAL fluid was used for cytokine assay and the lung tissues were collected for further analysis.

Preparation of SB203580. SB203580 was purchased from Selleck Chemicals, dissolved with DMSO (Sigma-Aldrich, Merck KGaA) according to the manufacturer’s protocol and diluted with PBS as a working solution. A final concentration of 2% DMSO was introduced in the cell culture media for each group, and 10% DMSO in solution was used for administration into the mouse model. There were no signs of cell toxicity and mouse mortality with the concentrations used in vitro and in vivo (data not shown).

Wet/dry weight ratio. The wet and dry weights (W) of the left lung tissues were measured prior to and following drying at 65°C for 48 h. Water content was obtained by calculating the W/D weight ratio.

Lung histology. Lung tissue was fixed in 4% paraformaldehyde and sections of 5 µm thickness were placed onto glass slides and stained with hematoxylin and eosin (Beyotime Institute of Biotechnology, Shanghai, China), according to the manufacturer’s protocol, for histopathological examination. The lung histology was viewed under a light photomicroscope and evaluated for pathological changes using a double-blind method. The severity of lung injury was evaluated using a semiquantitative histological index, including alveolar edema, hemorrhage, alveolar septal thickening and infiltration of polymorphonuclear leukocytes. Each item was divided into four grades from 0 to 3 (0, normal; 1, mild; 2, moderate; 3, severe) and then calculated for a total acute lung injury score (24).

Western blot analysis. The collected cells (1x10^6 cells/ml) were incubated with 100 µl radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology) supplied with protease inhibitor phenylmethylsulfonyl fluoride (Beyotime Institute of Biotechnology) for 30 min on ice. The proteins of the lung tissues were extracted using a Nuclear and Cytoplasmic Protein Extraction kit (Beyotime Institute of Biotechnology) according to the manufacturer’s protocol. Protein concentration was determined by bicinchoninic assay protein assay kit (Beyotime Institute of Biotechnology). Each 20 µg protein sample was resolved on a 10% SDS-PAGE gel. The protein was transferred onto polyvinylidene fluoride membrane blots (Merck Millipore; Merck KGaA), and...
the blots were incubated with blocking buffer (Shanghai Beyotime Institute of Biotechnology) for 1 h at room temperature, followed by incubation with the indicated primary antibodies against NLRP3 (1:1,000; NBP2-12446; Novus Biologicals, LLC, Littleton, CO, USA), caspase-1 (1:1,000; Ab1872; Abcam, Cambridge, MA, USA), caspase-3 (1:1,000; 9665s; Cell Signaling Technology, Inc.), Toll-like receptor (TLR)2 (1:1,000; ab108998; Abcam), TLR4 (1:1,000; se-293072; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), nuclear factor (NF)‑κB p65 (1:1,000; 3033p; Cell Signaling Technology, Inc.), p‑p38 (1:1,000; 4511S; Cell Signaling Technology, Inc.) and MAPK p38 (1:1,000; 4511S; Cell Signaling Technology, Inc.) at 4°C overnight. The antibody anti‑mouse β‑actin (1:1,000; BM0627; Boster Biological technology, Pleasanton, CA, USA) was used for internal loading control and blots were incubated with stripping buffer at 37°C for 15 min. The membranes were incubated with horseradish peroxidase‑conjugated secondary antibodies (1:1,000; anti‑rabbit:A0208; anti‑mouse A0216; Beyotime Institute of Biotechnology) for 1 h at room temperature. Immune reactivity was visualized using an enhanced chemiluminescent reagent (Beyotime Institute of Biotechnology). Band intensity was quantitatively analyzed by densitometric analysis on ImageJ software version 1.37 (National Institutes of Health, Bethesda, MD, USA).

RT‑qPCR. cDNA was synthesized from 1 μg total RNA with a RevelTra Ace qPCR RT Master Mix kit (Toyobo Life Science, Osaka, Japan). RT‑qPCR was performed using SYBR‑Green PCR Master Mix‑Plus (Toyobo Life Science, Osaka, Japan). All the primers were synthesized by Shanghai BioSune Biotechnology Co. Ltd. Primer sequences are listed in Table I. qPCR reaction was performed on a 7500 Real‑Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) under the condition of 95°C 1 min followed by 40 cycles of 95°C 15 sec, 60°C 60 sec, 72°C 45 sec. The expression level was quantified using the 2−ΔΔCq method (25), relative to the internal control β‑actin.

ELISA assay for cytokines. IL‑1β, tumor necrosis factor (TNF)‑α and IL‑6 expression levels in the BAL fluid or the supernatant of treated cells were measured by ELISA assays (IL‑1β: Mouse: MLB00C, rat: RLB00; TNF‑α: Mouse: MT000B; IL‑6: Mouse: M6000B, rat: R6000B; R&D Systems Inc, Minneapolis, MN, USA) according to the manufacturer’s protocols.

Immunofluorescence staining. RAW264.7 (1x10⁵ cells/ml) were stimulated with 1 μg/ml LPS for 4, 8, 12 and 24 h. Following treatment, the cells were incubated with fixing buffer and were blocked with blocking buffer (Shanghai Beyotime Institute of Biotechnology) for 30 min at room temperature. Subsequently, the cells were incubated with primary antibodies against rabbit anti‑NLRP3 (1:1,000; NBP2-12446; Novus Biologicals, LLC) and mouse anti‑caspase‑1 (1:1,000; sc-514; Santa Cruz Biotechnology, Inc.) for 2 h at 4°C. The cells were incubated with secondary antibodies Cy3‑conjugated anti‑rabbit IgG (1:1,000; A0516; Shanghai Beyotime Institute of Biotechnology) and FITC‑conjugated anti‑mouse IgG (1:1,000; A0568; Shanghai Beyotime Institute of Biotechnology) for 1 h at room temperature following incubation with the primary antibody and washing. DAPI was used for staining nuclei for 10 min at room temperature. Finally, the stained cells were visualized under a fluorescence microscope (Olympus Corporation, Tokyo, Japan).

Flow cytometry analysis. Pyroptotic cells were characterized by greater expression of cleaved caspase‑1 and positive propidium iodide (PI) staining (26) and early apoptotic cells were Annexin V+PI− (27). Detection of apoptotic and pyroptotic cells by flow cytometry was performed with Annexin V: FITC Apoptosis Detection Kit I (556547; BD Pharmingen; BD Biosciences, San Jose, CA, USA) and FLICA 660‑YVAD‑FMK far‑red caspase‑1 reagent (9122; ImmunoChemistry Technologies, LLC, Bloomington, MN, USA) according to the manufacturer’s protocols in vitro (BD Pharmingen; BD Biosciences). Briefly, the cells (1x10⁵ cells/ml) were resuspended in 100 μl 1X binding buffer and incubated with 5 μl FITC‑Annexin V (FL1 channel) and 5 μl PI in the dark for 20 min at room temperature. The stained cells were washed with PBS twice and fixed in 4% paraformaldehyde. To analyze pyroptotic cells, a 150 μl single cell suspension was incubated with 5 μl FITC‑conjugated Annexin V, 5 μl PI (FL2 channel) and 5 μl FLICA 660‑YVAD‑FMK far‑red caspase‑1 reagent (FL4 channel) in the dark at room temperature for 20 min, then washed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. Analysis was performed on a FACScan cytometer (Becton Dickinson; BD Biosciences), and data were analyzed with FlowJo software version 7.6 (FlowJo LLC, Ashland, OR, USA).

Statistical analysis. All experimental values were presented as the mean ± standard error of the mean. Statistical comparison between two groups was performed by Student’s t‑test, and one‑way analysis of variance followed by Bonferroni post hoc

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer sequences (5′‑3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse‑IL‑1β</td>
<td>Forward AGACGTTCAGGCAGGCAGTA</td>
</tr>
<tr>
<td></td>
<td>Reverse AGGGTGTCACTGTCCTCACCC</td>
</tr>
<tr>
<td>Mouse‑TNF‑α</td>
<td>Forward AGCGCATGGAATCTCAAGAC</td>
</tr>
<tr>
<td></td>
<td>Reverse GTGGTTGAGGAAGCAGGTAGT</td>
</tr>
<tr>
<td>Mouse‑IL‑6</td>
<td>Forward CCAGTGTGCTTCTTGGGACT</td>
</tr>
<tr>
<td></td>
<td>Reverse GGTCGTGTGGAGAGTTACCTCG</td>
</tr>
<tr>
<td>Mouse‑β‑actin</td>
<td>Forward GTGCTATGTGGCTCTAGACTTNG</td>
</tr>
<tr>
<td>Rat‑IL‑1β</td>
<td>Forward AAAATGCTTCTGCTGGTCTCTT</td>
</tr>
<tr>
<td></td>
<td>Reverse TCCTGTGGCTCTCCCTTG</td>
</tr>
<tr>
<td>Rat‑IL‑6</td>
<td>Forward AGTTGCTTCTTGGGACTGA</td>
</tr>
<tr>
<td></td>
<td>Reverse ACTGCTGTGTGGTGGTGG</td>
</tr>
<tr>
<td>Rat‑β‑actin</td>
<td>Forward TGTCACCAACTGGGAGCAGTA</td>
</tr>
<tr>
<td></td>
<td>Reverse GGTTGTTGAAGCTTTCAAAA</td>
</tr>
</tbody>
</table>

IL, interleukin; TNF, tumor necrosis factor.
analyses was performed among multiple groups for parametric data. P<0.05 was considered to indicate a statistically significant difference.

Results

Intraperitoneal injection of p38 MAPK inhibitor SB203580 suppresses murine acute lung injury and inflammation. To establish an acute lung injury mouse model, 8- to 10-week-old male mice were injected with 5 mg/kg LPS intratracheally (i.t.). The mice injected with PBS were used as controls. Massive inflammatory infiltrates, perivascular edema and severe alveolar space destruction were observed compared to the PBS-treated group 24 h following LPS injection (Fig. 1A). However, pretreatment with the p38 MAPK inhibitor SB203580 significantly reversed the severity of acute lung injury compared with the mice that received LPS treatment alone (Fig. 1A and B). Additionally, LPS treatment significantly induced more total BAL protein content (Fig. 1C) and cell counts (Fig. 1D). The weight loss (Fig. 1E) and lung wet/dry ratio (Fig. 1F) were also significantly elevated after i.t. LPS injection. The beneficial effects were consistent with the reduced total BAL protein content (Fig. 1C), cell counts (Fig. 1D), weight loss (Fig. 1E) and lung wet/dry ratio (Fig. 1F) in the group of mice that received both SB203580 and LPS.

Blockage of the p38 MAPK signaling pathway attenuates the expression of proinflammatory cytokines and the NLRP3 inflammasome in the inflamed murine lung tissues. To determine whether the reduced acute lung injury and inflammation in the SB203580-treated mice was supported by the decreased expression of proinflammatory cytokines, IL-1β, tumor necrosis factor (TNF)-α and IL-6 expression levels in BAL and lung tissues were measured by ELISA and RT-qPCR analysis. Supporting the observation above, it was demonstrated that the expression levels of IL-1β (Fig. 2A and B), TNF-α (Fig. 2C and D) and IL-6 (Fig. 2E and F) were greatly elevated at the mRNA and protein levels in the mice treated with LPS. However, blockage of p38 MAPK signaling pathway by SB203580 pretreatment significantly attenuated their expression (Fig. 2).

IL-1β is a downstream proinflammatory cytokine of the NLRP3 inflammasome and caspase-1 activation (28). To further investigate the effects of p38 MAPK signaling pathway blockage on the NLRP3 inflammasome, the relative protein expression levels of NLRP3, pro-caspase-1, cleaved-caspase-1 (Fig. 3A) and TLR2 (Fig. 3B) was analyzed by western blot analysis and the mRNA of NLRP3 (Fig. 3C) and TLR2 (Fig. 3D) by RT-qPCR. SB203580 pretreatment significantly reversed the LPS-induced upregulation of NLRP3, cleaved caspase-1 and TLR2, indicating a beneficial role of blockage of the p38 MAPK signaling pathway in reducing the formation of the NLRP3 inflammasome and pyroptosis.

Figure 1. p38 MAPK inhibitor SB203580 suppresses acute lung injury and inflammation in mice after i.t. injection of LPS. All parameters were measured at 24 h following the i.t. LPS treatment. (A) Representative images of the histology of lung tissues by H&E staining. Black arrows: Thickened alveolar septal; blue arrows: Alveolar hemorrhage and red arrows: infiltrated polymorphonuclear leukocytes (magnification, x200). (B) Lung pathological score in terms of lung injury and inflammation. (C) Total protein content and (D) total cell counts in BAL; (E) weight loss and (F) ratio of lung Wet/Dry were analyzed. Data are presented as the mean ± standard error of the mean. "P<0.01, ""P<0.001 vs. PBS group; "#P<0.05, "##P<0.01 vs. LPS group, n=5 per group. BAL, bronchoalveolar lavage fluid; i.t., intratracheal; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase.

LPS treatment increases the expression of NLRP3 and caspase-1 in macrophages. To further confirm the effects of LPS in inducing macrophage pyroptosis, the mouse macrophage cell line, RAW264.7 cells were treated, with 1 µg/ml LPS for 4, 8, 12, and 24 h. The NLRP3 expression was analyzed by immunofluorescence staining. As a result,
Figure 2. p38 MAPK inhibitor SB203580 suppresses IL-1β, TNF-α and IL-6 expression in mice following the i.t. injection of LPS. Twenty-four hours following SB203580 i.p. and LPS i.t. treatment, the lung and BAL fluids were collected. IL-1β (A) mRNA and (B) protein expression levels; TNF-α (C) mRNA and (D) protein expression levels and IL-6 (E) mRNA and (F) protein expression levels were analyzed by RT-qPCR analysis and by ELISA analysis, respectively. Data are presented as the mean ± standard error of the mean. **P<0.01, ***P<0.001 vs. PBS group; #P<0.05, ##P<0.01 vs. LPS group, n=5 mice per group. BAL, bronchoalveolar lavage fluid; i.p., intraperitoneal; i.t., intratracheal; IL, interleukin; LPS, lipopolysaccharide; TNF, tumor necrosis factor.

Figure 3. p38 MAPK inhibitor SB203580 suppresses caspase-1, NLRP3 and TLR2 expression in mice following i.t. injection of LPS. The pro-caspase-1, cleaved caspase-1, NLRP3 (A), NF-κB and TLR2 and TLR4 (B) were analyzed by western blot analysis following LPS treatment. NLRP3 (C) and TLR2 (D) mRNA expression levels were analyzed by RT-qPCR analysis. **P<0.01, ***P<0.001 vs. PBS group; #P<0.05 vs. LPS group, n=5 per group. IL, interleukin; i.t., intratracheal; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κ-light-chain-enhancer of activated B cells; NLRP, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing; TLR, Toll-like receptor.
the NLRP3-expressing cells were increased 4 h following LPS treatment that was gradually increased from 10.1±1.1% untreated cells to a maximal 20.2±1.7% cells treated for 24 h (P<0.01; Fig. 4A and B). In addition, the increasing number of NLRP3+ and cleaved caspase-1+ cells was observed by immunofluorescence staining following LPS treatment, indicating a role of LPS in NLRP3 inflammasome formation and activation (Fig. 4C).

**Blockage of p38 MAPK signaling pathway reverses the LPS-induced expression of NLRP3 and caspase-1 in macrophages.** Pyroptosis and early apoptosis of NR8383 after treatment were determined by flow cytometry. Further analysis indicated that LPS treatment resulted in 1.7-fold increases in caspase-1+PI+ pyroptotic cells as well as Annexin V+PI+- early apoptotic cells (Fig. 5A and B). The present analysis further indicated that pretreatment with SB203580 significantly reversed LPS-induced caspase-1+PI+ pyroptotic cells (Fig. 5A and C) but enhanced LPS-induced Annexin V+PI+- apoptotic cells (Fig. 5B and D). Thus, SB203580 treatment reduced cell pyroptosis but increased cell apoptosis by blockage of the p38 MAPK signaling pathway. LPS induced uncontrolled lung inflammation, possibly by inducing more cell pyroptosis and less cell apoptosis through p38 MAPK signaling, but this needs to be investigated further.

Additional analysis by western blot revealed that the blockage of p38 MAPK signaling pathway suppressed LPS-induced p38 MAPK activation (Fig. 6A) and inhibited the LPS-induced upregulation of NLRP3 and TLR2 proteins (Fig. 6B), consistent with the results of pyroptosis analyzed by flow cytometry (Fig. 5). However, higher expression levels of cleaved caspase-3 were detected in the cells treated with both SB203580 and LPS (Fig. 6C), which was in line with the results analyzed by flow cytometry, demonstrating a larger Annexin V+PI- apoptotic cell population following SB203580 pretreatment (Fig. 5B and D).

Further analysis of cytokines in the supernatant and the cell lysate of the treated cells indicated that LPS treatment induced higher mRNA expression levels of IL-1β and IL-6 (Fig. 7A and B, respectively) and higher protein expression levels (Fig. 7C and D). However, the elevated expression of IL-1β and IL-6 were significantly suppressed by SB203580 pretreatment (Fig. 7; P<0.05), further supporting the effects of p38 MAPK blockage in reducing macrophage pyroptosis in vitro, but this needs to be validated further.

---

**Figure 4.** LPS treatment increases NLRP3 expression in macrophages in vitro in a time-dependent manner. RAW264.7 were treated with 1 µg/ml LPS for 4, 8, 12, and 24 h. The untreated cells were used as controls. The expression of NLRP3 protein was analyzed by immunofluorescence staining. (A) Representative image of NLRP3 expression levels in cells treated at different time points and (B) quantification of them following LPS treatment. Data are presented as a ratio of NLRP3+ cells to the number of nuclei in 7 random selected fields n=5 per group. "P<0.05, "P<0.01 vs. untreated cells. (C) LPS treatment increases the formation of NLRP3 inflammasomes, and NLRP3 protein was colocalized with the cleaved caspase-1. Red: NLRP3; Green: Cleaved caspase-1; Blue: DAPI-stained nuclei. White arrow indicates NLRP3 inflammasome. LPS, lipopolysaccharide; NLRP, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing.
Discussion

Our previous study revealed that LPS can upregulate the expression of Toll-like receptor 4 (TLR4), myeloid differentiation protein 2 (MD-2), TNF-α, IL-6 and IL-1β in the rat alveolar macrophage cell line NR8383 (29,30) because IL-1β is mainly released from activated macrophages (31) and is a downstream cytokine of activation of inflammasome and pyroptosis (28). Therefore, it was hypothesized that LPS may induce release of IL-1β through macrophage pyroptosis, which is partially responsible for the uncontrolled lung inflammation in ALI/ARDS. To address this issue, in the present study, the effects of LPS on macrophage pyroptosis and lung inflammation was investigated in vitro and in vivo. The in vivo results indicated that LPS i.t. treatment significantly increased excessive lung inflammation and neutrophil infiltration, in association with increased caspase-1 cleavage and active IL-1β release. A similar result was also observed in RAW264.7 and NR8383 macrophage cell lines, in which NLRP3 and cleaved caspase-1 were upregulated and colocalized within the intracellular NLRP3 inflammasome following LPS treatment. Thus, LPS not only induced excessive lung inflammation through increasing macrophage and neutrophil recruitment but also caused a pyroptosis-biased macrophage death and subsequent IL-1β release.

The p38 MAPK signaling pathway has been suggested to be involved in the inflammatory response of ALI/ARDS (20,21). The production of many cytokines, including IL-1β, TNF-α and IL-6, which serve a key role in ALI/ARDS is mainly via the p38 MAPK signaling pathway (32). A number of anti-inflammatory medications work by targeting p38 MAPK (33, 34). Inhibition of p38 MAPK downregulated the IL-1β and reduced acute injury in intestinal ischemia reperfusion rats (35). In addition, blocking p38 downregulated the apoptosis of endothelia or epithelial cells producing protective effects on pulmonary alveolar-capillary barrier permeability (36-38). However, the exact mechanism of the p38 MAPK signaling pathway in inflammatory response and regulation remains to be elucidated. There are relatively few studies on the regulation of p38 MAPK for NLRP3 inflammasome and alveolar macrophage pyroptosis in the ALI/ARDS. In a recent study, NLRP3 gene knockout blocked NF-κB and the MAPK signaling pathway in a chronic unpredictable mild stress-induced depression mouse model (39). The results in the present study indicated

Figure 5. p38 MAPK inhibitor SB203580 suppresses caspase-1 expression but increased Annexin V+ cell population in vitro. The rat macrophage cell line NR8383 was treated with 1 µg/ml LPS for 4 h with/without pretreatment with 10 µM SB203580. The caspase-1 and Annexin V+ cells were measured by flow cytometry. (A) LPS increased caspase-1 expression which was reversed by pretreatment with SB203580. (B) LPS increased Annexin V+PI- early apoptotic cells and pretreatment with p38 MAPK inhibitor SB203580 enhanced this. (C) Quantitative analysis of caspase-1+PI+ pyroptotic cells and of (D) Annexin V+PI- apoptotic cells. Data are presented as the mean ± standard error of the mean. **P<0.01 vs. the untreated control group; #P<0.05, ##P<0.01 vs. the LPS-treated group, n=3 per group. LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase.
Figure 6. p38 MAPK inhibitor SB203580 suppresses the expression of NLRP3 and cleavage of caspase-1 in vitro. The rat macrophage cell line NR8383 was treated with 1 μg/ml LPS for 4 h with/without pretreatment with 10 μM SB203580. Protein expression levels of (A) p-p38, (B) NLRP3 and TLR2/TLR4 and (C) caspase-3 and cleaved-caspase-3, were analyzed by western blot analysis. Quantitative analysis for (D) p-p38, (E) TLR2, (F) cleaved-caspase-3 and (G) NLRP3 was performed, and data are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01 vs. the untreated control. *P<0.05 vs. the LPS treated group. n=3 per sample. LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; NLRP, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing; p, phosphorylated; TLR, Toll-like receptor.

Figure 7. p38 MAPK inhibitor SB203580 suppresses the expression of IL-1β and IL-6 in the LPS-treated macrophages. The rat macrophage cell line NR8383 was treated with 1 μg/ml LPS for 4 h with/without pretreatment with 10 μM SB203580. The mRNA expression levels of (A) IL-1β and (B) IL-6 in the treated cells were measured by RT-qPCR. The protein expression levels of (C) IL-1β and (D) IL-6 in the cell supernatants were measured by ELISA. Data are presented as the mean ± standard error of the mean, n=3 per group. ***P<0.001 vs. the untreated control group; *P<0.01 and **P<0.001 vs. the LPS-treated group, n=3 per group. IL, interleukin; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase.
that LPS treatment activated NLRP3 and IL-1β expression and activation through the p38 MAPK signaling pathway because blocking the p38 MAPK signaling pathway through SB203580 pretreatment reversed the LPS-induced upregulation of TLR2, NLRP3, caspase-1, IL-1β and IL-6 in NR8383 cells. The suppressed p38 MAPK signaling pathway was associated with less caspase-1+PI+ pyroptotic cell population as analyzed by flow cytometry.

Thus, the blockade of p38 MAPK signaling pathway has the potential to suppress excessive lung inflammation by inhibiting inflammatory macrophage pyroptosis-biased cell death. This finding may encourage further studies of the beneficial role of p38 MAPK signal block in inhibiting uncontrolled lung inflammation in the ALI/ARDS animal model. I.p. pretreatment with SB203580 significantly suppressed acute lung injury, which was characterized by reduced alveolar edema, hemorrhage, alveolar septal thickening and infiltration of polymorphonuclear leukocytes compared with the mice that received LPS treatment alone. Consistent with the pathological observation, NLRP3 and TLR2 expression and caspase-1 cleavage in lung tissue were significantly reduced following SB203580 pretreatment. In addition, IL-1β, TNF-α and IL-6 expression levels were attenuated, supporting the role of p38 MAPK signaling in LPS-induced acute lung injury and excessive lung inflammation. Previous studies indicated that TLR2/TLR3/TLR4/NF-κB signaling pathway was involved in NLRP3 inflammasome activation in LPS-induced macrophages (40,41). However, notable decreases in TLR4 expression levels were not evident, suggesting the possibility of reduced involvement of the TLR4/NF-κB signaling pathway in p38 MAPK blockade.

It should be noted that greater cell apoptosis was observed following treatment with both LPS and p38 MAPK inhibitor compared with LPS treatment alone. The results were demonstrated by a larger Annexin V+PI- cell population and greater cleavage of pro-caspase-3 in the apoptotic cells treated with both p38 MAPK inhibitor and LPS. Apoptosis can prevent the leakage of pro-inflammatory mediator, proteases, reactive oxygen species production and lysozymes which contribute to promote and maintain self-tolerance and the resolution of lung inflammation (42,43). Alveolar macrophages release the cytokines IL-8, TNF-α and IL-6 which not only directly induce lung injury but also recruit the neutrophils into the lung tissue as chemokines to aggravate the damage (44,45). In contrast to the results in endothelial or epithelial cells (36-38), in macrophages it has been demonstrated that blocking the p38 MAPK signaling pathway enhances macrophage apoptosis and cleavage of caspase-3. The results suggested that inhibition of the p38 MAPK signaling pathway may promote a shift in macrophage cell death from proinflammatory pyroptosis towards a noninflammatory apoptosis process which may contribute to the attenuated acute lung injury and excessive inflammation in ALI/ARDS. However, it is important to maintain an optimal balance between pyroptosis and apoptosis during disease progression and this needs further research.

In conclusion, blocking the p38 MAPK signaling pathway may ameliorate acute lung injury and lung inflammation, partially through suppressing macrophage pyroptosis (Fig. 8). The results of the present study may provide a rationale for ALI/ARDS immunotherapy through modulation of p38 MAPK signaling pathway and macrophage pyroptosis.

**Acknowledgements**

The authors would like to thank the Experimental Center of Fudan University, Zhongshan Hospital (Shanghai, China) for their assistance and cooperation during the present study.

**Funding**

The present study was supported by a research grant from the National Natural Science Foundation of China and the Shanghai Three-Year Plan of the Key Subjects Construction in Public Health-Infectious Diseases and Pathogenic Microorganism to LZ (grant nos. 81270137 and 81300054) and support from Zhongshan Hospital, Fudan University in China to ZJ (grant no. A654116001).

**Availability of data and materials**

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

**Authors’ contributions**

DL performed the experiments, experimental design, data assembly, analysis and manuscript writing. ZJ participated in experimental design, data interpretation and manuscript writing. WR participated in the generation of ideas and data interpretation. LZ participated in the generation of the hypothesis and...
data interpretation and was responsible for the overall direction of the work. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The experimental protocols were approved by the Laboratory Animal Care and Use Committee at the Medical College of Fudan University, Zhongshan Hospital (Shanghai, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.